CDK4 and breast carcinoma: This trend suggests that PLK1 could be a potential direct or indirect therapeutic target in HR-positive breast cancer even though the gene expression analyses of the current study were derived from breast cancer cohorts that were not exposed to CDK4/6 inhibitors.